Give the medicine its full name.

The ingredient and the brand answer different questions

Tirzepatide names the ingredient; Mounjaro and Zepbound name products containing it.

Ask which health problem the particular product is approved to treat. Also ask whether it comes in an injection pen or a small medicine bottle. The ingredient’s name alone does not answer those questions.

Each brand has its own approved uses

As of September 26, 2026, Mounjaro’s approved uses include improving blood sugar control in type 2 diabetes.

Its label also covers reducing major heart and stroke events in adults with that disease who are at high risk.

Zepbound is approved to help adults lose excess weight and keep it off. The approval covers adults diagnosed with obesity. It also covers adults diagnosed with overweight if they have a related health problem. Treatment goes alongside eating fewer calories and being more active.

Zepbound is also approved for adults with obesity who have moderate or severe obstructive sleep apnea.

Sleep apnea means repeated breathing pauses during sleep; obstructive means airflow is blocked.

A container is not proof of what is inside

A vial is a small medicine bottle. As of September 26, 2026, approved Zepbound and compounded tirzepatide can both come in vials. The bottle alone cannot tell you which product it holds or whether that product is approved.

On that date, the FDA had approved no generic version of tirzepatide. The term generic means a copy that has received approval as an alternative to a brand-name medicine.

Ask the pharmacist to identify the exact product. Keep its name and form together in your notes.